StemRIM

Tokyo Stock Exchange 4599.T

StemRIM Free Cash Flow Yield on January 31, 2025: -9.95%

StemRIM Free Cash Flow Yield is -9.95% on January 31, 2025, a -385.37% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

StemRIM 52-week high Free Cash Flow Yield is 5.73% on June 26, 2024, which is 157.64% above the current Free Cash Flow Yield.
StemRIM 52-week low Free Cash Flow Yield is -11.12% on December 26, 2024, which is -11.73% below the current Free Cash Flow Yield.
StemRIM average Free Cash Flow Yield for the last 52 weeks is -2.14%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Tokyo Stock Exchange: 4599.T

StemRIM

CEO	Mr. Masatsune Okajima
IPO Date	Aug. 9, 2019
Location	Japan
Headquarters	Saito Bio-Incubator
Employees	45
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Key trends

Past 5 years